194 related articles for article (PubMed ID: 31140152)
1. Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H; Lekbaby B; Fares N; Augustin J; Attout T; Schnuriger A; Cassard AM; Panasyuk G; Perlemuter G; Bieche I; Vacher S; Selves J; Péron JM; Bancel B; Merle P; Kremsdorf D; Hall J; Chemin I; Soussan P
Hepatol Int; 2019 Jul; 13(4):454-467. PubMed ID: 31140152
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma.
Wang Y; Yang F; Shang J; He H; Yang Q
Sci Rep; 2021 Jul; 11(1):15175. PubMed ID: 34312475
[TBL] [Abstract][Full Text] [Related]
3. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.
Zhao YJ; Wu LY; Pang JS; Liao W; Chen YJ; He Y; Yang H
Bioengineered; 2021 Dec; 12(1):3978-3992. PubMed ID: 34288818
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma.
Webster NJG; Kumar D; Wu P
Sci Rep; 2024 Jan; 14(1):2500. PubMed ID: 38291075
[TBL] [Abstract][Full Text] [Related]
5. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma.
Tremblay MP; Armero VE; Allaire A; Boudreault S; Martenon-Brodeur C; Durand M; Lapointe E; Thibault P; Tremblay-Létourneau M; Perreault JP; Scott MS; Bisaillon M
BMC Genomics; 2016 Aug; 17(1):683. PubMed ID: 27565572
[TBL] [Abstract][Full Text] [Related]
6. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
Lee J; Seo G; Hur W; Yoon SK; Nam SW; Lee JH
Anticancer Res; 2020 Apr; 40(4):2033-2042. PubMed ID: 32234894
[TBL] [Abstract][Full Text] [Related]
7. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.
Liu Z; Li W; Pang Y; Zhou Z; Liu S; Cheng K; Qin Q; Jia Y; Liu S
EBioMedicine; 2018 Dec; 38():57-68. PubMed ID: 30391496
[TBL] [Abstract][Full Text] [Related]
8. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
9. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
Shen Q; Eun JW; Lee K; Kim HS; Yang HD; Kim SY; Lee EK; Kim T; Kang K; Kim S; Min DH; Oh SN; Lee YJ; Moon H; Ro SW; Park WS; Lee JY; Nam SW
Hepatology; 2018 Apr; 67(4):1360-1377. PubMed ID: 29059470
[TBL] [Abstract][Full Text] [Related]
10. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma.
Wang XQ; Luk JM; Leung PP; Wong BW; Stanbridge EJ; Fan ST
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):483-9. PubMed ID: 15701831
[TBL] [Abstract][Full Text] [Related]
11. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.
Shen Q; Nam SW
BMB Rep; 2018 Feb; 51(2):57-58. PubMed ID: 29397868
[TBL] [Abstract][Full Text] [Related]
12. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.
Huang S; Luo K; Jiang L; Zhang XD; Lv YH; Li RF
Sci Rep; 2021 Dec; 11(1):23356. PubMed ID: 34857818
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
14. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
[TBL] [Abstract][Full Text] [Related]
15. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
16. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.
Lu X; Feng X; Man X; Yang G; Tang L; Du D; Zhang F; Yuan H; Huang Q; Zhang Z; Liu Y; Strand D; Chen Z
Clin Cancer Res; 2009 May; 15(10):3287-96. PubMed ID: 19447873
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
18. Regulation of a TGF-β1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells.
Wu J; Lu M; Li Y; Shang YK; Wang SJ; Meng Y; Wang Z; Li ZS; Chen H; Chen ZN; Bian H
Oncogene; 2016 Oct; 35(42):5468-5479. PubMed ID: 27041581
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma.
He F; Li J; Xu J; Zhang S; Xu Y; Zhao W; Yin Z; Wang X
J Exp Clin Cancer Res; 2015 May; 34(1):47. PubMed ID: 25975202
[TBL] [Abstract][Full Text] [Related]
20. Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.
Yin J; Wang L; Zhu JM; Yu Q; Xue RY; Fang Y; Zhang YA; Chen YJ; Liu TT; Dong L; Shen XZ
Oncotarget; 2016 Apr; 7(16):21939-51. PubMed ID: 26959880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
